NCT00551187View on ClinicalTrials.gov

A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)

PHASE2CompletedINTERVENTIONAL
Enrollment

620

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Cervical CancerVulvar CancerVaginal CancerGenital WartsHuman Papillomavirus Infection
Interventions
BIOLOGICAL

V504

V504 0.5 ml injection in 3 dose regimen for 6 month treatment period.

BIOLOGICAL

Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine

Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 ml injection in 3 dose regimen for 6 month treatment period.

BIOLOGICAL

Comparator: Placebo (unspecified)

V504 Placebo in 3 dose regimen for 6 month treatment period.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00551187 - A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) | Biotech Hunter | Biotech Hunter